Evidence map›Paper›PMID 33932069›Full record

ArticleCancer science2021

NAD(P)HX epimerase downregulation promotes tumor progression through ROS/HIF-1α signaling in hepatocellular carcinoma.

Bo Sun, Lei Yu, Cong Xu, Yi-Ming Li, Yan-Rong Zhao, Mo-Mo Cao, Lian-Yue Yang

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Research progress of stem cells in the treatment of atherosclerosis.Frontiers in cell and developmental biology · 2025
    Review
  6. Targeting inflammation as cancer therapy.Journal of hematology & oncology · 2024
    Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Bo SunLiver Cancer Laboratory, Department of Surgery, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0002-7999-7071
Lei YuLiver Cancer Laboratory, Department of Surgery, Xiangya Hospital, Central South University, Changsha, China.
Cong XuLiver Cancer Laboratory, Department of Surgery, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0002-9571-326X
Yi-Ming LiLiver Cancer Laboratory, Department of Surgery, Xiangya Hospital, Central South University, Changsha, China.
Yan-Rong ZhaoLiver Cancer Laboratory, Department of Surgery, Xiangya Hospital, Central South University, Changsha, China.
Mo-Mo CaoLiver Cancer Laboratory, Department of Surgery, Xiangya Hospital, Central South University, Changsha, China.
Lian-Yue YangLiver Cancer Laboratory, Department of Surgery, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0002-8805-872X
Central South University · CN

Funding

Key Project of National Nature Science Foundation of China 81330057National Key R&D Program of China 2016YFC0902400National Natural Science Foundation of China 81773139National Science & Technology Major Project 2017ZX10203207-002-003Specialized Research Fund for Doctoral Program of Higher Education of China 20130162130007
6 · The paper itself

Abstract

Reactive oxygen species (ROS) derived from aberrant tumor metabolism could contribute to tumor invasion and metastasis. NAD(P)HX Epimerase (NAXE), an epimerase that allows the repair of damaged forms of antioxidant NADPH, is a potential cellular ROS scavenger and its role in tumor development is still elusive. Here, we found that NAXE is significantly downregulated in hepatocellular carcinoma (HCC) tissues and cell lines. NAXE downregulation is associated with poor clinicopathological characteristics and is an independent risk factor for overall and disease-free survival of HCC patients after liver resection. In addition, low NAXE expression could identify worse prognosis of HCC patients before vascular invasion or in early stages of disease. In particularly, low NAXE expression in HCC is markedly associated with microvascular invasion (MVI) and its combination with MVI predicts poorer prognosis of HCC patients after liver resection. Furthermore, in vitro and in vivo experiments both showed that knockdown of NAXE expression in HCC cells promoted migration, invasion, and metastasis by inducing epithelial-mesenchymal transition (EMT), whereas NAXE overexpression causes the opposite effects. Mechanistically, low NAXE expression reduced NADPH levels and further caused ROS level increase and hypoxia-inducible factor-1α (HIF-1α) activation, thereby promoting invasion and metastasis of HCC by facilitating EMT. What is more, the tumor-promoting effect of NAXE knockdown in HCC xenograft can be abolished by giving mice N-acetyl-l-cysteine (NAC) in drinking water. Taken together, our findings uncovered a tumor suppressor role for NAXE in HCC by scavenging excessive ROS and inhibiting tumor-promoting signaling pathways, suggesting a new strategy for HCC therapy by targeting redox signaling.

Indexed as

AcetylcysteineAnalysis of VarianceAnimalsCarcinoma, HepatocellularCell MovementDisease-Free SurvivalDisease ProgressionDown-RegulationEpithelial-Mesenchymal TransitionFemaleFree Radical ScavengersHeterograftsHumansHypoxia-Inducible Factor 1, alpha SubunitLiver NeoplasmsMaleAcetylcysteineFree Radical ScavengersHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitNADPNAXE protein, humanNeoplasm ProteinsRacemases and EpimerasesReactive Oxygen Speciesepithelial-mesenchymal transitionmicrovascular invasionprognosisredox signalingsolitary large hepatocellular carcinoma

Identifiers

PMID33932069
PMCPMC8253267
OpenAlexW3157657766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.